Antibodies and hematologic malignancies

Cancer Journal

Volumn 14, Issue 3, 2008, Pages 184-190

  Smith, Mitchell R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Immunotoxin; Leukemia; Lymphoma; Monoclonal antibody; Myeloma; Radioimmunotherapy

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; CD30 ANTIGEN; CD40 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENILEUKIN DIFTITOX; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; INOTUZUMAB OZOGAMICIN; LENALIDOMIDE; LEXATUMUMAB; LUMILIXIMAB; MAPATUMUMAB; MILATUZUMAB; MONOCLONAL ANTIBODY; OBLIMERSEN; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; IMMUNOTOXIN; LEUKOCYTE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOXICITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; BLOOD DISEASE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION;

EID: 52649157043     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318173a5f9     Document Type: Review

References (92)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83:435-445.
2. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol. 2000;27:9-16.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
4. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 2007;26:3629-3636.
5. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043.
6. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6: 443-446.
7. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99:754-758.
8. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135-3143.
9. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
10. Hainsworth JD, Litchy S, Burris r HA, et al. Rituximab as first-line maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
11. Witzig T, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2007;20:1103-1108.
12. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
13. Hochster HS, Weller E, Gascoyne R, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lym-phoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106:A349.
14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
15. Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
16. Pfreundschuh M, Trümper L, Osterborg A, et al; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
17. Sehn L, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23: 5027-5033.
18. Ghielmini M, Hsu Schmitz S-F, Cogliatti SB, et al. Prolonged treatment with rituximab significantly improves event free survival. Blood. 2002; 99:604, Abstract.
19. Gordan L, Grow WB, Braylan RC, et al. A Phase II Trial of Individualized pharmacokinetic dosing of rituximab maintenance for patients with CD-20 positive lymphoproliferative disorders. Blood. 2002;99: Abstract [1400].
20. Kahl BS, Williams ME, Hong F, et al. Preliminary pharmokinetic (PK) analysis of the Eastern Cooperative Oncology Group protocol E4402: rituximab extended schedule or re-treatment (RESORT). Blood. 2007; 110:A3420.
21. van Oers M, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301.
22. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Per Cancer Research Network. J Clin Oncol. 2005;23:1088-1094.
23. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood. 2002;101:949 -954.
24. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800 - 809.
25. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
26. Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007;92:1127-1130.
27. Kaufmann H, Raderer M, Wöhrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;104:2269-2271.
28. Reddy N, Hernandez-Ilizaliturri FJ, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36-45.
29. Hooijberg E, Sein JJ, van den Berk PCM, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res. 1995;55:2627-2634.
30. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002; 117:828-834.
31. Khan K, Emmanouilides C, Benson DM Jr, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res. 2006; 12:7046-7053.
32. van der Kolk L, Grillo-López AJ, Baars JW, et al. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia. 2003;17:1658-1664.
33. Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma. 2000;1:57-61.
34. Smith MR, Fang J, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Mol Cancer Ther. 2004;3:1693-1699.
35. Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, et al. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol. 2004;127:519-530.
36. van Delft M, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389-399.
37. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood. 2008 [Epub ahead of print].
38. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA. 2007;104:19512-19517.
39. Jacene H, Filice R, Kasecamp W, et al. Comparison of 90Y-ibritu-momab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-1776.
40. Davies A. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene. 2007;26:3614-3628.
41. Fisher R, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573.
42. Horning S, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23.
43. Kaminski M, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
44. Witzig TE, Flinn IW, Gordon L, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
45. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19: 3918-2938.
46. Press O, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131. Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2007;24:4143-4149.
47. Leonard J, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696.
48. Smith MR, Zhang L, Gordon LI, et al. Phase II study of R-CHOP followed by 90Y-Ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Blood. 2007;110:A349.
49. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:90-95.
50. Gopal A, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25:1396-1402.
51. Goldenberg D, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158-163.
52. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004;15:2868-2878.
53. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094-1100.
54. Bowles J, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006;108:2648-2654.
55. Stone M, Sausville EA, Fay JW, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 1996;88:1188-1197.
56. Grossbard M, Multani PS, Freedman AS, et al. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:2392-2398.
57. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10:5327-5334.
58. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005;233:5044-5051.
59. Strauss S, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22. antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24:3880-3886.
60. Linden O, Hindorf C, Cavallin-Ståhl E, et al. Dose-fractionated radio-immunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11:5215-5222.
61. Fayad L, Patel H, Verhoef G, et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood. 2006;108:A2711.
62. Kreitman R, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
63. Byrd J, O'Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:4448-4455.
64. Byrd J, Castro J, O'Brien S, et al. Comparison of results from a Phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood. 2006; 108:A14.
65. Kreitman R, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636.
66. Dang N, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:4095-4102.
67. Dang N, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007;6:439-447.
68. Waldmann T. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007;26:699-703.
69. Bartlett N, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848-1854.
70. Ansell SM, Horwitz S, Engert A, Khan KD, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764-2769.
71. Vonderheide R, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
72. Advani R, Forero-Torres A, Furman RR, et al. SGN-40(Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma:evidence of anti-tumor activity from a Phase I study. Blood. 2006;108:A695.
73. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtu-zumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004;104:938-955.
74. Demko S, Summers J, Keegan P, et al. FDA drug approval summary: alemtuzumab as single agent treatment for B cell CLL. Oncologist. 2008;13:167-174.
75. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first line therapy for CLL. J Clin Oncol. 2007;25:5616 - 5623.
76. Hainsworth J, Vazquez ER, Spigel DR, et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008;112:1288-1295.
77. Keating M, Cazin B, Coutré S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205-213.
78. Shore T, Harpel J, Schuster MW, et al. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biol Blood Marrow Transplant. 2006;12:868-875.
79. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for immunotherapy of B cell neoplasms. Clin Cancer Res. 2007;13:5556s- 5563s.
80. Starlets D, Gore Y, Binsky I, et al. Cell surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107:4807-4816.
81. Stein R, Qu Z, Cardillo TM, et al. Anti-proliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B cell malignancies. Blood. 2004;104.
82. Czuczman M, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005;233:4390-4398.
83. Leonard J, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007;18:1216-1223.
84. Rech J, Repp R, Rech D, et al. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk Lymphoma. 2006;47:2147-2154.
85. Griffith TS, Rauch, Charles T, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol. 1999;162:1597-2605.
86. Younes A, Vose JM, Zelenetz AD, et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma. Blood. 2005;106:A489.
87. Smith MR, Jin F, Joshi I. Bortezomib sensitizes non-Hodgkin's lym-phoma cells to apoptosis induced by antibodies to TRAIL receptors TRAIL-R1 and -R2. Clin Cancer Res. 2007;13:5528s-5534s.
88. Pagano L, Fianchi L, Caira M, et al. The role of gemtuzumab ozogami-cin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26:3679-3690.
89. Feldman E, Kalaycio M, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003;17:314-318.
90. Feldman E, Brandwein J, Stone R, et al. Phase III randomized multi-center study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110-4116.
91. Jurcic J, Larson, SM, Sgouros, G, et al. Targeted alpha particle immu-notherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
92. Ganjoo K, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47: 998-1005.